MarketWatch

Cure HHT's Advocacy Effort, Support Helps NIH-Sponsored PATH Trial Become First Successful, Large-Scale Randomized Trial For HHT

The MarketWatch News Department was not involved in the creation of this content. Cure HHT plays pivotal role in the NIH-sponsored PATH Trial becoming the first successful, large-scale randomized ...

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the ...
Nature

Cure HHT

Article ‘Count’ and ‘Share’ for Cure HHT based on listed parameters only. The articles listed below published by authors from Cure HHT, organized by journal and article, represent the research output ...
Science Daily

Clinical trial successfully repurposes cancer drug for hereditary bleeding disorder

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...
Morningstar

Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary ...

Treatment strategies for HHT are limited to symptom management as there are currently no approved therapeutics for the disease. “DIAG723 represents a powerful new approach to treating HHT, supported ...
GEN

Rare Bleeding Disorder, HHT, Treated Successfully with Cancer Drug in Clinical Trial

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...
ABC30 Action News

HHT: Just a Nosebleed, or Something More?

PITTSBURGH (KFSN) -- HHT is a genetic disorder of the blood vessels. In severe cases, it can lead to sudden bleeding or stroke. Researchers say HHT affects more than one in 5,000 people, but 90 ...
EurekAlert!

Cleveland Clinic study is first to show success in treating rare blood disorder

Wednesday, September 18, 2024, CLEVELAND: A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare ...
Business Wire

Feinstein Institutes Research Shows Cancer Drugs Could Help With Vascular Disease

MANHASSET, N.Y.--(BUSINESS WIRE)--A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia (HHT) – a rare genetic bleeding condition ...
Healio

Ace the Case: A 46-year-old woman with diagnosed HHT, an epistaxis severity score of 4.15/10, and iron deficiency anemia

Please provide your email address to receive an email when new articles are posted on . Strategically developed to promote the care team’s awareness of HHT and galvanize optimization of HHT-associated ...
Healio

Ace the Case: A 61-year-old woman with HHT, severe ongoing epistaxis, evidence of gastrointestinal bleeding, and severe pain in her right hip

Strategically developed to promote the care team’s awareness of HHT and galvanize optimization of HHT-associated IDA management, this series of Ace the Case sessions will highlight key teaching points ...